LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of 7,000 shares of its newly designated Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into an aggregate of 7,000,000 shares of its common stock and unregistered common stock purchase warrant
Related Questions
How will the issuance of Series C convertible preferred stock affect the dilution of existing shareholders?
How does this $7 million capital raise compare to PharmaCyte's recent financing activities and to similar biotech funding rounds in the market?
What are the conversion terms and timeline for the preferred stock to become common shares, and how might that impact the share supply?